Genencell Founder Implicated in 'Kim Seung-won Lobbying Allegation' Sentenced to 4 Years in Second Trial
Conviction Overturned on Concealment of Criminal Proceeds
"Clear Lobbying to the Ministry of Food and Drug Safety Through Kim Seungwon"
Kang, the founder of Genencell who was implicated in the "COVID-19 clinical trial approval lobbying" allegation involving Kim Seung-won, a member of the Democratic Party of Korea and former nominee for Minister of Justice, was sentenced to a prison term and taken into custody following the appeal trial.
Professor Kang, founder of Genencell, who was implicated in the lobbying allegations for approval of COVID-19 clinical trials involving Kim Seungwon, a member of the Democratic Party and former nominee for Minister of Justice, appeared at the second trial sentencing hearing for breach of trust charges held at the Seoul High Court in Seocho-gu, Seoul on the 30th. Photo by Yonhap News.
View original imageOn the 30th, the 7th Criminal Division of the Seoul High Court (Presiding Judge Koo Hoe-geun) sentenced Professor Kang to four years in prison and a fine of 40 million won on charges including breach of trust under the Act on the Aggravated Punishment of Specific Economic Crimes and violation of the Act on Regulation and Punishment of Criminal Proceeds Concealment. Previously, Professor Kang had been tried without detention after receiving a suspended sentence at the first trial, but was taken into custody in court after the prison sentence was handed down.
In the first trial, he was sentenced to three years in prison, suspended for five years.
The court stated, "Drug development, which has a direct impact on the human body, requires the highest level of care, yet false data was submitted merely for the purpose of obtaining approval, which is deserving of severe criticism." The court further added, "He attempted to exaggerate the results of new drug development amid a national disaster like COVID-19 to secure substantial profits, ultimately earning real gains, while many investors who purchased shares suffered significant losses."
The appellate panel determined that Professor Kang clearly requested clinical trial approval handled by the Commissioner of the Ministry of Food and Drug Safety through candidate Kim. In exchange, a total of 600 million won was paid and disguised as a legitimate acquisition of convertible bonds from broker Yang’s company. The court observed, "Even though some value in the company stock can be recognized, it is difficult to distinguish between a legitimate transaction and a payment for influence," and thus recognized the entire 600 million won as a reward for brokerage. The first trial had previously acquitted him on this point, ruling it was difficult to definitively categorize the money as a bribe for clinical trial approval.
The court maintained the first trial’s judgment concerning the submission of false data. It found that two reports submitted by Professor Kang contained some false entries and omitted the fact that hamsters had died, qualifying as deception. As in the first trial, Professor Kang was also found guilty of attempted fraud related to COVID-19 support funds and obstruction of the Institutional Review Board’s work.
The conviction for violating the Capital Markets Act by using undisclosed important information, based on text messages exchanged with broker Yang, was also upheld.
The judgment of the first trial was maintained regarding the breach of trust charge related to Genencell’s convertible bond acquisition in April 2020, which the prosecution had appealed. Some of the evidence was collected illegally, while the rest was deemed insufficient to prove a crime.
Professor Kang was put on trial for submitting documents containing false information about hamster experiments and intentionally omitting side effects during the COVID-19 treatment development process, thereby obtaining a Korean Intellectual Property Office patent and clinical trial approval from the Ministry of Food and Drug Safety. He is also standing trial at the Seoul Western District Court for conspiring with Yang to request expedited clinical trial approval from Assemblyman Kim and promising to provide 5 million won as a political donation.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Assemblyman Kim was investigated in October 2021 on allegations of requesting clinical trial approval for Genencell’s treatment from the Minister of Food and Drug Safety at the request of Yang. In December 2024, however, the Seoul Western District Prosecutors’ Office decided to suspend indictment, acknowledging that the 5 million won political donation was given as compensation for influence-peddling, but finding that the lobbying itself could not be conclusively deemed illegal.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.